QLGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
QLGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Qualigen Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:
1. Operating Margin %A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Qualigen Therapeutics's Operating Margin % for the quarter that ended in Sep. 2024 was %. As of today, Qualigen Therapeutics's Piotroski F-Score is 1.
For the Biotechnology subindustry, Qualigen Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Qualigen Therapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Qualigen Therapeutics's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Qualigen Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Qualigen Therapeutics's Operating Margin % for the quarter that ended in Sep. 2024 is calculated as:
Operating Margin % | = | Operating Income (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | -1.269 | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Warning Sign:
Piotroski F-Score of 1 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Qualigen Therapeutics has an F-score of 1. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of Qualigen Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael S. Poirier | director, officer: Chairman, President and CEO | 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011 |
Amy S. Broidrick | director | 1440 VALLE GRANDE, ESCONDIDO CA 92025 |
Kurt H Kruger | director | 100 FOXBOROUGH BLVD, SUITE 240, FOXBOROUGH MA 02035 |
Tariq Arshad | officer: SVP/Chief Medical Officer | 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011 |
Christopher L. Lotz | officer: Vice President of Finance, CFO | 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 90211 |
Emery Sidney W Jr | director | C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011 |
Richard A. David | director | 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011 |
Wajdi Abdul-ahad | officer: VP, R&D, CSO | 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011 |
Shishir K. Sinha | officer: VP of Operations | 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011 |
Sekisui Diagnostics, Llc | 10 percent owner | 1 WALL STREET, BURLINGTON MA 01803 |
Matthew E Korenberg | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Noah Doyle | director | C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096 |
John W Beck | officer: Chief Financial Officer | C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067 |
Jeffrey S Benjamin | officer: VP of Finance | 3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096 |
William M. Merino | director | C/O RITTER PHARMACEUTICALS INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067 |
From GuruFocus
By Marketwired • 08-15-2023
By Marketwired • 11-01-2024
By GlobeNewswire • 09-06-2024
By GlobeNewswire • 09-26-2024
By Marketwired • 11-19-2024
By sperokesalga sperokesalga • 06-05-2023
By Marketwired • 11-25-2024
By GlobeNewswire GlobeNewswire • 04-21-2023
By Marketwired • 09-06-2024
By GuruFocus Research • 02-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.